Resize Text Search
  • Schedule an Appointment
  • Find a Doctor
  • Locations
Patient Information
Doctor Appointment

Research & Innovation Logo

Summa Neuroscience Physician Offers Stem Cell

Susana Bowling, M.D., system medical director for the neuroscience service line and Director of the Stroke Center at Summa Akron City Hospital, is offering a Phase II clinical trial to ischemic stroke patients to investigate the safety and efficacy of MultiStem® cells, a proprietary stem cell product developed by Athersys, Inc. MultiStem cells are a biologic product manufactured from human stem cells obtained from adult bone marrow donors, a non-embryonic tissue source. The trial is investigating the ability of MultiStem treatment to improve outcomes for patients following an ischemic stroke. A goal of the treatment is to control the immune response triggered during the acute phase of a stroke and to reduce inflammation, decrease neuronal cell death and promote cell survival and regeneration. The randomized Phase II trial will examine the safety and efficacy of a single IV infusion of MultiStem cells relative to a placebo infusion in patients 18 to 83 years of age within 48 hours of symptom onset.

In the 2013 Executive Summary of Heart Disease and Stroke Statistics, the American Heart Association reported that every year approximately 850,000 people in the U.S. experience a new or recurrent stroke. On average, someone in the U.S. experiences a stroke every 40 seconds, and someone dies of one every four minutes. Last year, Summa treated 945 stroke patients. The main treatment for ischemic stroke remains thrombolysis with intravenous tissue plasminogen activator and it must be administered to patients shortly after the event occurs. Current data suggest that less than 4% of stroke patients receive IV tPA due to the time limitation of this therapy and delay of patients’ arrival to the hospital. Treatments that can be effectively administered during a longer time frame are needed. In contrast to thrombolytic therapy, MultiStem cells may be administered 1 to 2 days following the ischemic stroke. 

Further details on this clinical trial can be obtained from click here

Information on Athesys, Inc. and MultiStem cells can be obtained here.